CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TEP1 (ImmuneEditome ID:7011)

1. Gene summary of enriched editing regions for TEP1

check button Gene summary
Gene informationGene symbol

TEP1

Gene ID

7011

GeneSynonymsTLP1|TP1|TROVE1|VAULT2|p240
GeneCytomap

14q11.2

GeneTypeprotein-coding
GeneDescriptiontelomerase protein component 1|TROVE domain family, member 1|p80 telomerase homolog|telomerase protein 1
GeneModificationdate20230517
UniprotIDQ99973;G3V591;G3V5X7;H0YJF6;H0YIY9;G3V2A4;G3V470
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr14:20366170-20367930:-ENST00000553365.4ENSG00000129566.11TEP1splicingAluY,AluSx1chr14:20366170-20367930:-.alignment


Top

2. Tumor-specific enriched editing regions for TEP1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr14:20366170-20367930:-BRCAEER7.3648e-11image
ENSG00000129566.11,TEP1BRCAEAG7.7505e-11image
chr14:20366170-20367930:-COADEER2.3761e-09image
ENSG00000129566.11,TEP1COADEAG1.4838e-09image
chr14:20366170-20367930:-KIRCEER1.0835e-09image
ENSG00000129566.11,TEP1KIRCEAG1.7962e-09image
chr14:20366170-20367930:-KIRPEER9.7305e-05image
ENSG00000129566.11,TEP1KIRPEAG9.7305e-05image
chr14:20366170-20367930:-LIHCEER1.8471e-04image
ENSG00000129566.11,TEP1LIHCEAG1.8471e-04image
chr14:20366170-20367930:-LUSCEER1.3641e-04image
ENSG00000129566.11,TEP1LUSCEAG1.3641e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr14:20366170-20367930:-BLCAPathEER5.0197e-032.3054e-030.1527image
ENSG00000129566.11,TEP1BLCAPathEAG5.0197e-032.3054e-030.1527image
ENSG00000129566.11,TEP1KIRPPathEAG3.0454e-054.7863e-060.2804image
chr14:20366170-20367930:-KIRPPathEER3.0454e-054.7863e-060.2804image
chr14:20366170-20367930:-LUADPathEER9.1001e-032.0734e-020.1016image
ENSG00000129566.11,TEP1LUADPathEAG9.0960e-032.0726e-020.1016image
chr14:20366170-20367930:-LUSCPathEER4.7266e-021.1034e-020.1146image
ENSG00000129566.11,TEP1LUSCPathEAG4.7266e-021.1034e-020.1146image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr14:20366170-20367930:-LUSCEER1.9428e-023.5630e-028.2725e-02image
ENSG00000129566.11,TEP1LUSCEAG1.9428e-023.5630e-028.2725e-02image

Top

3. Enriched editing regions and immune related genes for TEP1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr14:20366170-20367930:-CESCEERENSG00000168894,RNF1810.33283.4595e-067.1973e-170.4561imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr14:20366170-20367930:-CESCEERENSG00000034510,TMSB100.32725.4313e-062.9930e-150.4339imageNNNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr14:20366170-20367930:-CESCEERENSG00000239672,NME10.26225.7253e-042.9266e-130.4042imageNNNME1B_cells_memoryGSVA_HALLMARK_MYC_TARGETS_V2
chr14:20366170-20367930:-CESCEERENSG00000228499,TMSB10P10.24691.2687e-035.4766e-210.5062imageNNNAB_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr14:20366170-20367930:-CESCEERENSG00000117691,NENF0.24651.4679e-032.2856e-130.4059imageNNNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr14:20366170-20367930:-CESCEERENSG00000143947,RPS27A0.21866.4706e-033.9219e-140.4176imageNNNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr14:20366170-20367930:-CESCEERENSG00000118640,VAMP80.21177.8229e-033.4031e-150.4331imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr14:20366170-20367930:-CESCEERENSG00000115350,POLE40.21228.0055e-031.9228e-140.4222imageNNNAMacrophages_M2GSVA_HALLMARK_DNA_REPAIR
chr14:20366170-20367930:-CESCEERENSG00000125743,SNRPD20.21328.2288e-031.2701e-130.4099imageNNNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr14:20366170-20367930:-CESCEERENSG00000108826,MRPL270.20061.4170e-025.7536e-150.4299imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for TEP1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000129566.11,TEP1
CESCEAGIRENSG00000116455.9chr1111439889:111441389:111441498:111441604-0.26622.0134e-042.6724e-10-0.4011imageNAUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr14:20366170-20367930:-
CESCEERIRENSG00000116455.9chr1111439889:111441389:111441498:111441604-0.26622.2485e-042.6724e-10-0.4011imageNNNAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr14:20366170-20367930:-
CESCEERIRENSG00000198830.6chr126473482:26473585:26473702:26473732-0.27521.0664e-031.0758e-18-0.4836imageNNHMGN2Dendritic_cells_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
ENSG00000129566.11,TEP1
CESCEAGIRENSG00000198830.6chr126473482:26473585:26473702:26473732-0.27529.7733e-041.0758e-18-0.4836imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184HMGN2Dendritic_cells_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr14:20366170-20367930:-
CESCEERIRENSG00000103335.15chr1688717721:88717808:88719573:88719721-0.20951.5130e-021.4713e-13-0.4442imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr14:20366170-20367930:-
CESCEERIRENSG00000137965.6chr178659318:78660691:78662703:78662756-0.20031.6043e-024.5907e-10-0.4044imageNNIFI44T_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000129566.11,TEP1
CESCEAGIRENSG00000104529.13chr8143588990:143590081:143590607:143590729-0.33864.1577e-074.0724e-14-0.4548imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr14:20366170-20367930:-
CESCEERA3ENSG00000162144.5chr1161350990:61351132:61348817:61349120:61348817:613496430.21663.3167e-022.0978e-150.4374imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr14:20366170-20367930:-
CESCEERIRENSG00000169592.10chr1630001211:30001530:30005367:30005435-0.21333.5543e-025.8503e-13-0.4057imageNNNAB_cells_memoryGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr14:20366170-20367930:-
CESCEERIRENSG00000215910.3chr111787387:11788047:11788242:11788378-0.19703.7442e-024.7810e-12-0.4079imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for TEP1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr14:20366170-20367930:-ACCEEREosinophils3.4971e-020.2423image
ENSG00000129566.11,TEP1ACCEAGEosinophils3.4971e-020.2423image
chr14:20366170-20367930:-BLCAEERT_cells_CD4_memory_activated3.9001e-060.2299image
ENSG00000129566.11,TEP1BLCAEAGT_cells_CD4_memory_activated3.9001e-060.2299image
chr14:20366170-20367930:-BRCAEERB_cells_naive2.3088e-06-0.1431image
ENSG00000129566.11,TEP1BRCAEAGB_cells_naive1.6009e-06-0.1453image
chr14:20366170-20367930:-CESCEERDendritic_cells_activated4.8675e-030.1619image
ENSG00000129566.11,TEP1CESCEAGDendritic_cells_activated4.8675e-030.1619image
chr14:20366170-20367930:-CHOLEERT_cells_CD4_naive2.2112e-030.5003image
ENSG00000129566.11,TEP1CHOLEAGT_cells_CD4_naive2.2112e-030.5003image
chr14:20366170-20367930:-COADEERB_cells_naive3.0888e-02-0.1304image
ENSG00000129566.11,TEP1COADEAGB_cells_naive3.2789e-02-0.1290image
chr14:20366170-20367930:-ESCAEERT_cells_regulatory_(Tregs)8.5482e-06-0.3428image
ENSG00000129566.11,TEP1ESCAEAGT_cells_regulatory_(Tregs)9.1506e-06-0.3417image
chr14:20366170-20367930:-GBMEERMacrophages_M06.3000e-03-0.2145image
ENSG00000129566.11,TEP1GBMEAGMacrophages_M06.3000e-03-0.2145image
chr14:20366170-20367930:-HNSCEERMacrophages_M24.3621e-030.1292image
ENSG00000129566.11,TEP1HNSCEAGMacrophages_M24.3621e-030.1292image
chr14:20366170-20367930:-KICHEERMacrophages_M09.4525e-030.3221image
ENSG00000129566.11,TEP1KICHEAGMacrophages_M09.4525e-030.3221image
chr14:20366170-20367930:-KIRCEERT_cells_gamma_delta1.9332e-040.1898image
ENSG00000129566.11,TEP1KIRCEAGT_cells_gamma_delta1.9353e-040.1898image
chr14:20366170-20367930:-KIRPEERMacrophages_M15.7378e-070.2905image
ENSG00000129566.11,TEP1KIRPEAGMacrophages_M15.7378e-070.2905image
chr14:20366170-20367930:-LAMLEERMonocytes1.1294e-02-0.2070image
ENSG00000129566.11,TEP1LAMLEAGMonocytes1.2087e-02-0.2051image
chr14:20366170-20367930:-LGGEERMacrophages_M23.6385e-02-0.0914image
ENSG00000129566.11,TEP1LGGEAGMacrophages_M23.5511e-02-0.0919image
chr14:20366170-20367930:-LIHCEERNK_cells_resting5.3884e-030.1500image
ENSG00000129566.11,TEP1LIHCEAGNK_cells_resting5.3884e-030.1500image
chr14:20366170-20367930:-LUADEERT_cells_CD4_memory_activated4.9463e-050.1777image
ENSG00000129566.11,TEP1LUADEAGT_cells_CD4_memory_activated4.9463e-050.1777image
chr14:20366170-20367930:-LUSCEERT_cells_CD4_memory_activated1.7180e-020.1074image
ENSG00000129566.11,TEP1LUSCEAGT_cells_CD4_memory_activated1.7180e-020.1074image
chr14:20366170-20367930:-MESOEERMast_cells_resting1.7437e-03-0.3426image
ENSG00000129566.11,TEP1MESOEAGMast_cells_resting1.7437e-03-0.3426image
chr14:20366170-20367930:-OVEERT_cells_CD86.2790e-030.1662image
ENSG00000129566.11,TEP1OVEAGT_cells_CD86.1042e-030.1668image
chr14:20366170-20367930:-PAADEERT_cells_regulatory_(Tregs)9.0736e-03-0.1956image
ENSG00000129566.11,TEP1PAADEAGT_cells_regulatory_(Tregs)9.0791e-03-0.1956image
chr14:20366170-20367930:-PCPGEERMacrophages_M23.7362e-03-0.2151image
ENSG00000129566.11,TEP1PCPGEAGMacrophages_M23.7362e-03-0.2151image
chr14:20366170-20367930:-PRADEERMast_cells_activated8.6280e-03-0.1176image
ENSG00000129566.11,TEP1PRADEAGMast_cells_activated8.6280e-03-0.1176image
chr14:20366170-20367930:-READEERDendritic_cells_resting2.1080e-020.2377image
ENSG00000129566.11,TEP1READEAGDendritic_cells_resting2.1080e-020.2377image
chr14:20366170-20367930:-SARCEERMacrophages_M21.0697e-030.2045image
ENSG00000129566.11,TEP1SARCEAGMacrophages_M21.0697e-030.2045image
chr14:20366170-20367930:-SKCMEERT_cells_CD81.4381e-020.1132image
ENSG00000129566.11,TEP1SKCMEAGT_cells_CD81.4381e-020.1132image
chr14:20366170-20367930:-STADEERT_cells_CD81.6394e-050.2235image
ENSG00000129566.11,TEP1STADEAGT_cells_CD81.1871e-050.2270image
chr14:20366170-20367930:-TGCTEERT_cells_regulatory_(Tregs)1.2318e-02-0.2026image
ENSG00000129566.11,TEP1TGCTEAGT_cells_regulatory_(Tregs)1.2318e-02-0.2026image
chr14:20366170-20367930:-THCAEERB_cells_naive2.9289e-020.0972image
ENSG00000129566.11,TEP1THCAEAGB_cells_naive2.9289e-020.0972image
chr14:20366170-20367930:-THYMEERMacrophages_M12.3330e-070.4654image
ENSG00000129566.11,TEP1THYMEAGMacrophages_M12.3330e-070.4654image
chr14:20366170-20367930:-UCECEERMacrophages_M11.5518e-030.2438image
ENSG00000129566.11,TEP1UCECEAGMacrophages_M11.1655e-030.2492image
chr14:20366170-20367930:-UCSEERMast_cells_activated1.0841e-030.4365image
ENSG00000129566.11,TEP1UCSEAGMast_cells_activated1.0841e-030.4365image
chr14:20366170-20367930:-UVMEERT_cells_follicular_helper4.9566e-02-0.2356image
ENSG00000129566.11,TEP1UVMEAGT_cells_follicular_helper4.9566e-02-0.2356image


Top

6. Enriched editing regions and immune gene sets for TEP1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr14:20366170-20367930:-KIRPEER1.6956e-02image5.2390e-030.1647image
ENSG00000129566.11,TEP1KIRPEAG1.6956e-02image5.2390e-030.1647image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr14:20366170-20367930:-BRCAEER1.1171e-080.17263.0369e-070.15501.1153e-030.09907.3252e-070.1500image
ENSG00000129566.11,TEP1BRCAEAG1.2184e-080.17223.3539e-070.15441.1657e-030.09865.7594e-070.1514image
ENSG00000129566.11,TEP1ESCAEAG4.0380e-060.35426.4481e-030.21395.3277e-080.41275.8523e-070.3817image
chr14:20366170-20367930:-ESCAEER3.8325e-060.35506.6198e-030.21324.6511e-080.41444.9969e-070.3839image
chr14:20366170-20367930:-LUADEER1.3329e-090.26293.1789e-050.18202.5316e-060.20541.4016e-150.3417image
ENSG00000129566.11,TEP1LUADEAG1.3329e-090.26293.1789e-050.18202.5316e-060.20541.4016e-150.3417image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr14:20366170-20367930:-BLCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER5.2933e-080.2696image
ENSG00000129566.11,TEP1BLCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG5.2933e-080.2696image
chr14:20366170-20367930:-BRCAGSVA_HALLMARK_GLYCOLYSISEER6.4573e-310.3414image
ENSG00000129566.11,TEP1BRCAGSVA_HALLMARK_GLYCOLYSISEAG5.5441e-310.3418image
chr14:20366170-20367930:-CESCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER8.0572e-060.2541image
ENSG00000129566.11,TEP1CESCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.0572e-060.2541image
chr14:20366170-20367930:-CHOLGSVA_HALLMARK_ADIPOGENESISEER9.5563e-030.4320image
ENSG00000129566.11,TEP1CHOLGSVA_HALLMARK_ADIPOGENESISEAG9.5563e-030.4320image
ENSG00000129566.11,TEP1COADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.2009e-030.1775image
chr14:20366170-20367930:-COADGSVA_HALLMARK_P53_PATHWAYEER1.3391e-040.2287image
chr14:20366170-20367930:-DLBCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0547e-03-0.4628image
ENSG00000129566.11,TEP1DLBCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.0547e-03-0.4628image
chr14:20366170-20367930:-ESCAGSVA_HALLMARK_HYPOXIAEER4.9969e-070.3839image
ENSG00000129566.11,TEP1ESCAGSVA_HALLMARK_HYPOXIAEAG5.8523e-070.3817image
ENSG00000129566.11,TEP1GBMGSVA_HALLMARK_PEROXISOMEEAG5.0309e-070.3838image
chr14:20366170-20367930:-GBMGSVA_HALLMARK_PEROXISOMEEER5.0309e-070.3838image
chr14:20366170-20367930:-HNSCGSVA_HALLMARK_APOPTOSISEER6.2845e-110.2911image
ENSG00000129566.11,TEP1HNSCGSVA_HALLMARK_APOPTOSISEAG6.2845e-110.2911image
ENSG00000129566.11,TEP1KICHGSVA_HALLMARK_APOPTOSISEAG5.3171e-03-0.3445image
chr14:20366170-20367930:-KICHGSVA_HALLMARK_APOPTOSISEER5.3171e-03-0.3445image
ENSG00000129566.11,TEP1KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.3665e-320.5553image
chr14:20366170-20367930:-KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.6218e-320.5550image
ENSG00000129566.11,TEP1KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1125e-080.3297image
chr14:20366170-20367930:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.1125e-080.3297image
ENSG00000129566.11,TEP1LAMLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG5.3809e-03-0.2269image
chr14:20366170-20367930:-LAMLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.7261e-03-0.2303image
ENSG00000129566.11,TEP1LGGGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.6404e-090.2490image
chr14:20366170-20367930:-LGGGSVA_HALLMARK_PANCREAS_BETA_CELLSEER7.2660e-090.2493image
ENSG00000129566.11,TEP1LIHCGSVA_HALLMARK_ADIPOGENESISEAG2.4263e-120.3665image
chr14:20366170-20367930:-LIHCGSVA_HALLMARK_ADIPOGENESISEER2.4263e-120.3665image
ENSG00000129566.11,TEP1LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.9070e-270.4514image
chr14:20366170-20367930:-LUADGSVA_HALLMARK_MTORC1_SIGNALINGEER2.9070e-270.4514image
chr14:20366170-20367930:-LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEER3.8453e-100.2774image
ENSG00000129566.11,TEP1LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEAG3.8453e-100.2774image
chr14:20366170-20367930:-MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.2930e-050.4638image
ENSG00000129566.11,TEP1MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.2930e-050.4638image
ENSG00000129566.11,TEP1OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG5.6506e-100.3665image
chr14:20366170-20367930:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.3032e-100.3670image
chr14:20366170-20367930:-PAADGSVA_HALLMARK_MTORC1_SIGNALINGEER2.0490e-050.3142image
ENSG00000129566.11,TEP1PAADGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.0507e-050.3142image
ENSG00000129566.11,TEP1PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.3774e-040.2522image
chr14:20366170-20367930:-PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER6.3774e-040.2522image
chr14:20366170-20367930:-PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER6.3775e-090.2565image
ENSG00000129566.11,TEP1PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG6.3775e-090.2565image
ENSG00000129566.11,TEP1SARCGSVA_HALLMARK_ANGIOGENESISEAG6.3238e-070.3071image
chr14:20366170-20367930:-SARCGSVA_HALLMARK_ANGIOGENESISEER6.3238e-070.3071image
ENSG00000129566.11,TEP1SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG6.5450e-090.2644image
chr14:20366170-20367930:-SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER6.5450e-090.2644image
chr14:20366170-20367930:-STADGSVA_HALLMARK_UV_RESPONSE_UPEER1.7059e-170.4256image
ENSG00000129566.11,TEP1STADGSVA_HALLMARK_UV_RESPONSE_UPEAG1.8928e-170.4251image
chr14:20366170-20367930:-TGCTGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.5520e-040.2860image
ENSG00000129566.11,TEP1TGCTGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG3.5520e-040.2860image
chr14:20366170-20367930:-THCAGSVA_HALLMARK_GLYCOLYSISEER1.7378e-150.3448image
ENSG00000129566.11,TEP1THCAGSVA_HALLMARK_GLYCOLYSISEAG1.7378e-150.3448image
ENSG00000129566.11,TEP1THYMGSVA_HALLMARK_P53_PATHWAYEAG1.8628e-060.4330image
chr14:20366170-20367930:-THYMGSVA_HALLMARK_P53_PATHWAYEER1.8628e-060.4330image
chr14:20366170-20367930:-UCECGSVA_HALLMARK_TGF_BETA_SIGNALINGEER9.7865e-04-0.2536image
ENSG00000129566.11,TEP1UCECGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.9031e-03-0.2386image
ENSG00000129566.11,TEP1UCSGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.0643e-02-0.3172image
chr14:20366170-20367930:-UCSGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.0643e-02-0.3172image
chr14:20366170-20367930:-UVMGSVA_HALLMARK_DNA_REPAIREER3.1096e-030.3485image
ENSG00000129566.11,TEP1UVMGSVA_HALLMARK_DNA_REPAIREAG3.1096e-030.3485image


Top

7. Enriched editing regions and drugs for TEP1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000129566.11,TEP1ACCAZD.0530EAG3.4270e-040.4001image
chr14:20366170-20367930:-ACCAZD.0530EER3.4270e-040.4001image
chr14:20366170-20367930:-BLCAAxitinibEER3.4956e-050.2066image
ENSG00000129566.11,TEP1BLCAAxitinibEAG3.4956e-050.2066image
ENSG00000129566.11,TEP1BRCAATRAEAG5.8846e-070.1514image
chr14:20366170-20367930:-BRCAATRAEER5.9849e-070.1513image
chr14:20366170-20367930:-CESCAZD6482EER4.2485e-080.3094image
ENSG00000129566.11,TEP1CESCAZD6482EAG4.2485e-080.3094image
chr14:20366170-20367930:-CHOLErlotinibEER1.9368e-04-0.5896image
ENSG00000129566.11,TEP1CHOLErlotinibEAG1.9368e-04-0.5896image
chr14:20366170-20367930:-COADCI.1040EER3.6104e-03-0.1753image
ENSG00000129566.11,TEP1COADAZD8055EAG5.1458e-03-0.1686image
ENSG00000129566.11,TEP1DLBCAZD6482EAG3.7648e-040.5022image
chr14:20366170-20367930:-DLBCAZD6482EER3.7648e-040.5022image
chr14:20366170-20367930:-ESCADocetaxelEER2.0411e-05-0.3289image
ENSG00000129566.11,TEP1ESCADocetaxelEAG2.4409e-05-0.3260image
chr14:20366170-20367930:-GBMKU.55933EER1.2776e-05-0.3365image
ENSG00000129566.11,TEP1GBMKU.55933EAG1.2776e-05-0.3365image
chr14:20366170-20367930:-HNSCCI.1040EER1.2473e-04-0.1733image
ENSG00000129566.11,TEP1HNSCCI.1040EAG1.2473e-04-0.1733image
ENSG00000129566.11,TEP1KICHABT.888EAG2.1059e-030.3775image
chr14:20366170-20367930:-KICHABT.888EER2.1059e-030.3775image
ENSG00000129566.11,TEP1KIRCBIRB.0796EAG2.3881e-110.3339image
chr14:20366170-20367930:-KIRCBIRB.0796EER2.5580e-110.3334image
ENSG00000129566.11,TEP1KIRPGSK.650394EAG3.1609e-100.3609image
chr14:20366170-20367930:-KIRPGSK.650394EER3.1609e-100.3609image
ENSG00000129566.11,TEP1LAMLJNK.9LEAG1.2074e-020.2052image
chr14:20366170-20367930:-LAMLJNK.9LEER1.1349e-020.2069image
ENSG00000129566.11,TEP1LGGATRAEAG4.3735e-070.2185image
chr14:20366170-20367930:-LGGATRAEER4.9697e-070.2175image
chr14:20366170-20367930:-LIHCGemcitabineEER2.5881e-060.2507image
ENSG00000129566.11,TEP1LIHCGemcitabineEAG2.5881e-060.2507image
ENSG00000129566.11,TEP1LUADBMS.509744EAG2.4557e-09-0.2587image
chr14:20366170-20367930:-LUADBMS.509744EER2.4557e-09-0.2587image
chr14:20366170-20367930:-LUSCErlotinibEER4.6772e-06-0.2048image
ENSG00000129566.11,TEP1LUSCErlotinibEAG4.6772e-06-0.2048image
chr14:20366170-20367930:-MESOA.770041EER5.5145e-03-0.3057image
ENSG00000129566.11,TEP1MESOA.770041EAG5.5145e-03-0.3057image
ENSG00000129566.11,TEP1OVAZD6482EAG3.6090e-110.3900image
chr14:20366170-20367930:-OVAZD6482EER3.6627e-110.3899image
chr14:20366170-20367930:-PAADCGP.082996EER1.2164e-020.1881image
ENSG00000129566.11,TEP1PAADCGP.082996EAG1.2162e-020.1881image
chr14:20366170-20367930:-PCPGAZD.2281EER7.1498e-040.2499image
ENSG00000129566.11,TEP1PCPGAZD.2281EAG7.1498e-040.2499image
chr14:20366170-20367930:-PRADGNF.2EER9.6375e-06-0.1972image
ENSG00000129566.11,TEP1PRADGNF.2EAG9.6375e-06-0.1972image
ENSG00000129566.11,TEP1READMG.132EAG1.1441e-03-0.3304image
chr14:20366170-20367930:-READMG.132EER1.1441e-03-0.3304image
ENSG00000129566.11,TEP1SARCCisplatinEAG1.1034e-07-0.3262image
chr14:20366170-20367930:-SARCCisplatinEER1.1034e-07-0.3262image
ENSG00000129566.11,TEP1SKCMGNF.2EAG1.1414e-12-0.3212image
chr14:20366170-20367930:-SKCMGNF.2EER1.1414e-12-0.3212image
chr14:20366170-20367930:-STADAZ628EER1.3422e-09-0.3105image
ENSG00000129566.11,TEP1STADAZ628EAG1.7332e-09-0.3085image
chr14:20366170-20367930:-TGCTGW.441756EER6.4004e-03-0.2202image
ENSG00000129566.11,TEP1TGCTGW.441756EAG6.4004e-03-0.2202image
chr14:20366170-20367930:-THCAAG.014699EER5.1480e-120.3013image
ENSG00000129566.11,TEP1THCAAG.014699EAG5.1480e-120.3013image
ENSG00000129566.11,TEP1THYMABT.263EAG8.7616e-080.4796image
chr14:20366170-20367930:-THYMABT.263EER8.7616e-080.4796image
chr14:20366170-20367930:-UCECA.770041EER7.1803e-06-0.3405image
ENSG00000129566.11,TEP1UCECA.770041EAG7.8494e-05-0.3007image
chr14:20366170-20367930:-UCSBMS.509744EER2.8576e-05-0.5412image
ENSG00000129566.11,TEP1UCSBMS.509744EAG2.8576e-05-0.5412image
chr14:20366170-20367930:-UVMEHT.1864EER8.4599e-05-0.4523image
ENSG00000129566.11,TEP1UVMEHT.1864EAG8.4599e-05-0.4523image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType